Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Tascilar, M ^a   Caspers, E ^a   Sturm, P D J ^a   Goggins, M ^b   Hruban, R H ^b   Offerhaus, G Johan A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Diagnosis; K ras; Molecular markers; p53; Pancreas cancer; Screening

Indexed keywords

PROTEIN P53; TELOMERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CONFERENCE PAPER; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENE MUTATION; HUMAN; LIVER METASTASIS; MICROSCOPY; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS JUICE; PRIORITY JOURNAL;

EID: 0032807639     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S107     Document Type: Conference Paper

References (70)

1. Warshaw AL, Fernandez-Del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65
2. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. The Lancet 1997; 349: 485-9.
3. DiGiuseppe JA, Yeo CJ, and Hruban RH. Molecular biology and the diagnosis and treatment of adenocarcinoma of the pancreas. Adv Anat Path 1996; 3:139.
4. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995; 221:721-31.
5. Brat DJ, Lillemoe KD, Yeo CJ et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22:163-9.
6. Cubilla A and Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976;36:2690-8.
7. Hruban RH, Digiuseppe JA. and Offerhaus GJA. K-ras mutations in pancreatic ductal proliferate lesions: Author's reply. Am J Path 1994;145:1548
8. Fearon ER and Vogelstein BA. A genetic model for colorectal tumorigenesis. Cell 1990;759-767.
9. Hruban RH, van Mansfeld ADM, Offerhaus GJA et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Path 1993; 143: 545-54.
10. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
11. DiGiuseppe JA, Hruban RH, Offerhaus GJA et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Path 1994; 144:889-95.
12. Tada M, Omata M, Kawai S et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer res 1993; 53: 2472-4.
13. DiGiuseppe JA, Hruban R, Goodman SN et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
14. Casey G, Yamanaka Y, Friess H et al. P53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993; 69: 151-60.
15. Lundin J, Nordling S, von Boguslawsky K et al. Prognostic value of immunohistochemical expresion of p53 in patients with pancreatic cancer. Oncology 1996;53: 104-11.
16. Rozenblum E, Schutte M, Goggins et al.Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-4.
17. Kern SE, Pietenpol JA, Thiagalingam S et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256:827-30.
18. Kern SE, Kinzler KW, Bruskin A et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991;252:1708-11.
19. Hahn SA, Schutte M, Hoque ATMS et al. DPC4, A candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-3.
20. Schutte M, Hruban RH, Hedrick L et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30.
21. Niehrs C. Mad connection to the nucleus. Nature 1996;381:561-2.
22. Derynck R, Gelbart WM, Harland RM et al. Nomenclature: vertebrate mediators of TGF beta family signals. Cell 1996;87:173-6.
23. wafl expression and growth inhibition by transforming growth factor β involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 1997; 57: 3929-34.
24. Hu YX, Watanabe H, Ohtsubo K et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 1997;3:1473-7.
25. Seymour A, Hruban RH, Redston MS et al. Allelotype of pancreatic adenocarcinoma.Cancer Res 1994;54:2761-4.
26. Huang L, Goodrow TL, Zhang S et al. Deletion and mutation analyses of the p16/MTS-1 tumor-suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996;56: 1137-41.
27. Kamb A, Gruis NA, Weaver-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
28. Schutte M, Hruban RH, Geradts J et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-30.
29. Huang L, Lang D, Geradts J et al. Molecular and immunochemical analyses of RB1 and Cyclin D1 in human ductal pancreatic carcinomas and cell lines. Molec Carcinogen 1996;15:85-95.
30. Goggins M, Hruban RH, and Kern SE. Relationship of BRCA2 germline mutation and pancreatic cancer intraductal lesions. Fourth Annual SPORE Meeting 1997; 4:30 (abstract).
31. Ozcelik H, Schmocker B, DiNicola N et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nature Genetics 1997;16:17-8.
32. Giardiello FM, Welsh SB, Hamilton SR et al. Increased risk of cancer in Peutz-Jeghers syndrome. N England J Med 1987;316: 1511-4.
33. Su GH, Hilgers W, Shekher MC et al. Allerations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998;58:2339-42.
34. Goggins M, Schutte M, Moskaluk CA et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
35. Goggins M, Offerhaus GJA, Hilgers W et al. Adenocarcinomas of the pancreas with DNA replication errors (RER+) are associated with a characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 1998;152:1501-7.
36. Parsons R, Li GM, Longley MJ et al. Hypermutabilily and mismatch repair deficiency in RER+ tumor cells. Cell 1993;75:1227-36.
37. Kunkel TA. Slippery DNA and diseases. Nature 1993; 365:207-8.
38. Fishel R, Lescoe MK, Rao MRS et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-38.
39. Leach FS, Nicotaides NC, Papadopoulaos N et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-36.
40. Kim H, Jen J, Vogelstein B et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-56.
41. Liu B, Nicolaides NC, Markowitz S et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instbility. Nature Genetics 1995; 9:49-55.
42. Burks RT, Kessis TD, Cho KR et al. Microsatellite instability in endometrial carcinoma. Oncogene 1994; 9:1163-1166.
43. Ottini L, Palli D, Falchetti M et al. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. Cancer Res 1997;57:4523-9.
44. Berthelémy P, Bouisson M, Escourrou J et al. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995;123:188-91.
45. Moskaluk CA, Hruban RH and Kern SE. P16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer res 1997;57:2140-3.
46. Tada M, Ohashi M, Shiratori Y et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterol 1996; 10:227-31.
47. Almoguera C, Shibata D, Forrester K et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;16:549-54.
48. Verlaan-de Vries M, Boogaard M, van den Elst H et al. A dot-blot screening procedure for mutated ras oncogenes using synthetic oligonucleotides. Gene 1986;50:313-20
49. Rall CJN, Yan Y, Graeme-Cook F et al. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas 1996;12:10-7.
50. Chung CH, Wilentz RE, Polak MM et al. Clinical significance of K-ras oncogene activation in ampullary neoplasms. J Clin Pathol 1996;49:460-4.
51. Wilentz RE, Chung CH, Sturm PDJ et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998; 82: 96-103.
52. van Laethem J-L, Vertongen P, Deviere J et al. Detection of c-Ki ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumors. Gut 1995; 36:781-7.
53. Sturm PDJ, Hruban RH, Ramsoekh TB et al. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998;186:247-53.
54. van Es JM, Polak MM, van den Berg FM et al. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. J Clin Pathol 1995;48:218-22.
55. Sturm PDJ, Rauws EAJ, Hruban RH et al. The clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. (Submitted)
56. Yamada T, Nakamori S, Ohzato H et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma:correlation with clinicopathological features. Clin canc research 1998; 4: 1527-32.
57. Hruban RH, Sturm PDJ, Slebos RJC et al. Can K-ras codon 12 mutations be used 10 distinguish benign bile duct proliferations from metastases in the liver? Am J Path 1997;151:943-9.
58. Iguchi H, Sugano K, Fukayama N et al. Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology 1996;110:221-6.
59. Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991;253:49-53.
60. Scarpa A, Capelli P, Mukai K et al. Pancreatic adenocarcinomas frequently show p53 gene mutations.Am J Surg Path 1993;142:1534-43.
61. DiGiuseppe JA, Hruban RH, Goodman, SN et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
62. Hameed M, Marrero AM, Conlon KC, et al. Expression of p53 nucleophosphoprotein in in situ pancreatic ductal adenocarcinoma: An immunochemical analysis of 100 cases. Lab Invest 1994; 70, 132A, 764 (Abstract).
63. Sturm PDJ, Tascilar M, Smit M et al. Diagnostic value of p53 immunocytlogy of endobiliary brush cytlogy: Paired cytlogy and tissue examined. (Submitted)
64. Iwao T, Hanada K, Tsuchida A, et al. The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations. Cancer 1998; 82: 1487-94.
65. Ishimaru S, Itoh M, Hanada K et al. Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma. Cancer 1996;77: 2233-9.
66. Wilentz RE, Geradts J, Maynard R et al. Inactivation of the p16 (INK4A) Tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression. Cancer Res 1998;58:4740-4.
67. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci 1998; 95:11891-6.
68. Mao L, Schoenberg MP, Scicchitano M et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271:659-62.
69. Zhou W, Sokoll W, Bruzek DJ et al. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 1998; 7:109-12.
70. Hiyama E, Kodama T, Shinbara K et al. Telomerase activity is detected in panceatic cancer but not in benign tumors. Cancer Res 1997;57:326-31